Intellia Therapeutics' stock surged 33.46% in pre-market trading on Monday, following positive analyst commentary on the company's clinical pipeline.
Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Intellia Therapeutics and maintained a price target of $29.00, citing upside potential from the Lonvo-z Phase 3 HAELO trial. This optimistic outlook likely fueled investor confidence and drove the stock's significant pre-market gain.